Meloxicam
- Generic Name
- Meloxicam
- Brand Names
- Anjeso, Mobic, Qmiiz, Vivlodex
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13N3O4S2
- CAS Number
- 71125-38-7
- Unique Ingredient Identifier
- VG2QF83CGL
- Background
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.
- Indication
Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.
Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
- Associated Conditions
- Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
- Conditions
- Participants With Acute Moderate to Severe Pain Following Abdominal Surgery
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Yangtze River Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 224
- Registration Number
- NCT06904248
- Locations
- 🇨🇳
Cangzhou People's Hospital, Cangzhou, China
🇨🇳The Third Xiangya Hospital Of Central South University, Changsha, China
🇨🇳Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China
Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Universidad Austral de Chile
- Target Recruit Count
- 68
- Registration Number
- NCT06704113
Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT06379165
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Phase II Study of Ovulation in Obese Women
- Conditions
- Pregnancy Prevention
- Interventions
- Other: calcium carbonate 750 milligram
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- InnovaGyn, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06306131
- Locations
- 🇺🇸
Carolina Women's Research and Wellness Center, Raleigh, North Carolina, United States
Pre vs Post Block in Total Knee Arthroplasty (TKA)
- Conditions
- Knee OsteoarthritisArthroplasty ComplicationsPostoperative Pain
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 84
- Registration Number
- NCT05974501
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery
- Conditions
- Pain, Post-operative
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05950152
- Locations
- 🇨🇳
the Third XiangYa Medical Hospital of Central South University, Changsha, Hunan, China
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
- Conditions
- Pregnancy Prevention
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- InnovaGyn, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05695352
- Locations
- 🇺🇸
Carolina Women's Research and Wellness Center, Raleigh, North Carolina, United States
Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Baudax Bio
- Target Recruit Count
- 19
- Registration Number
- NCT05315479
- Locations
- 🇺🇸
Research Center, Salt Lake City, Utah, United States
Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)
- Conditions
- Total Hip ReplacementTotal Knee Replacement
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 223
- Registration Number
- NCT05291598
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block
- Conditions
- Symptomatic Irreversible Pulpitis
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Alfarabi Colleges
- Target Recruit Count
- 250
- Registration Number
- NCT05097768
- Locations
- 🇸🇦
Vission Colleges, Jeddah, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.